BIO — Bio Rad Laboratories Cashflow Statement
0.000.00%
- $7.14bn
- $6.80bn
- $2.58bn
Annual cashflow statement for Bio Rad Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 47.8 | 85.8 | 108 | 106 | 42.9 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 669 | 194 | 375 | 455 | 532 |
| Capital Expenditures | -134 | -113 | -157 | -189 | -158 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -664 | -1,095 | 177 | 28.8 | -32.1 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | -797 | -1,208 | 20.2 | -160 | -190 |
| Financing Cash Flow Items | -23 | -14 | -14.9 | -34 | -3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -55.4 | 974 | -426 | -219 | -283 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -196 | -36.6 | -30.2 | 85.4 | 42.4 |